The startup develops therapeutics that target the protein palmitoylation and depalmitoylation pathways to modulate immune responses in autoimmune diseases and cancer immunotherapies. By focusing on novel protein acylation mechanisms, the company aims to enhance treatment efficacy for a range of immune-related disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Many autoimmune diseases and cancers lack effective treatments due to the complex and often dysregulated immune responses involved. Current therapies may have limited efficacy or significant side effects, highlighting the need for more targeted and precise approaches to modulate the immune system.
Solution
This startup is developing a therapeutic platform that targets protein palmitoylation and depalmitoylation pathways to modulate immune responses in autoimmune diseases and cancer immunotherapies. By selectively modulating these pathways, the company aims to re-balance the immune system, promoting immune tolerance in autoimmune disorders and enhancing anti-tumor immunity in cancer. This approach has the potential to improve treatment efficacy and reduce off-target effects compared to traditional immunomodulatory therapies. The company's focus on protein acylation mechanisms represents a novel strategy for developing a new generation of therapeutics.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases and cancer, as well as pharmaceutical companies seeking innovative immunomodulatory therapies.
Features
- Therapeutics targeting protein palmitoylation pathways.
- Therapeutics targeting protein depalmitoylation pathways.
- Modulation of immune responses in autoimmune diseases.
- Modulation of immune responses in cancer immunotherapies.
- Focus on novel protein acylation mechanisms.